Medigus Ltd. (NASDAQ:MDGS – Get Rating) saw a large decline in short interest in January. As of January 15th, there was short interest totalling 5,100 shares, a decline of 81.1% from the December 31st total of 27,000 shares. Based on an average daily volume of 33,600 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.9% of the shares of the company are short sold.
Medigus Trading Down 3.9 %
Shares of MDGS stock traded down $0.20 during midday trading on Monday, reaching $4.87. 4,600 shares of the company traded hands, compared to its average volume of 12,211. The firm's 50 day simple moving average is $5.89 and its two-hundred day simple moving average is $7.62. Medigus has a 1-year low of $4.45 and a 1-year high of $19.50. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.39 and a quick ratio of 1.33.
Get
Medigus alerts:
Medigus Dividend Announcement
The business also recently declared a dividend, which was paid on Wednesday, December 28th. Stockholders of record on Tuesday, December 20th were given a dividend of $0.85 per share. The ex-dividend date was Monday, December 19th. This represents a dividend yield of 12.9%.
Institutional Investors Weigh In On Medigus
A hedge fund recently bought a new stake in Medigus stock. Virtu Financial LLC acquired a new position in shares of Medigus Ltd. (NASDAQ:MDGS – Get Rating) in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 61,809 shares of the company's stock, valued at approximately $40,000. Virtu Financial LLC owned about 0.39% of Medigus at the end of the most recent reporting period. 9.18% of the stock is currently owned by hedge funds and other institutional investors.
About Medigus
(Get Rating)
Medigus Ltd., a technology-based company, provides medical-related devices and products in the United States, Europe, China, Israel, and internationally. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease. The company also develops biological gels to protect patients against biological threats and reduce the intrusion of allergens and viruses through the upper airways and eye cavities.
Read More
- Get a free copy of the StockNews.com research report on Medigus (MDGS)
- 4 High-Yield Dividend Kings For 2023
- Will 2023 be a Good Year for Goodyear Tire Stock?
- Lululemon Stock, Buying Opportunity on Lowered Guidance?
- Is Delta On Track To Hit A Fresh 52-Week High?
- Should You Add These Warren Buffett Stocks to Your Portfolio?
Receive News & Ratings for Medigus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medigus and related companies with MarketBeat.com's FREE daily email newsletter.
（Get Rating）